checkAd

     105  0 Kommentare SpineGuard Announces its Q3 2023 Revenue - Seite 2

    In the rest of the world, the product sales of the third quarter 2023 grew by +5% for the products and decreased by 33% when factoring in the interruption of royalties revenue related to the dental project.

    4,395 DSG units were sold in the first nine months of 2023 vs. 4,209 units in first nine months of 2022, which is a global growth of +4%. 1,596 units were sold in the United States representing 36% of total units.

    Cash position

    At September 30, 2023, cash and cash equivalents were € 4.0M.
    To continue bolstering its equity, the company is currently considering other funding opportunities, including a capital increase with retention of preferential subscription rights, rather than to use the Horizon equity line put in place on May 31, 2023 with Nice & Green's for an amount of € 7.5M, which remains undrawn at the date of this press release.

    Perspectives

    SpineGuard is focusing on the following priorities while investing selectively and with rigor:

    1. Boost commercial activities with PediGuard Threaded and the DSG-Connect platform
    2. Develop the DSG drill bit for a launch in 2024
    3. Codevelop the Sacro-Iliac DSG device and Smart Screw with Omnia Medical
    4. Implement the three-prong agreement recently signed with XinRong Medical for China
    5. Deploy the DSG technology in the surgical robotic and dental fields
    6. Initiate new strategic partnerships

    About SpineGuard

    Founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard is an innovative company deploying its proprietary radiation-free real time sensing technology DSG (Dynamic Surgical Guidance) to secure and streamline the placement of implants in the skeleton. SpineGuard designs, develops and markets medical devices embedding its technology. Over 95,000 surgical procedures have been secured worldwide thanks to DSG and twenty-five studies published in peer-reviewed scientific journals have demonstrated the multiple benefits DSG offers to patients, surgeons, surgical staff and hospitals. Building on these strong fundamentals and several strategic partnerships, SpineGuard is expanding the scope of its DSG technology to the treatment of scoliosis via anterior approach, sacroiliac joint fusion, dental implantology and innovations such as the « smart » pedicle screw and power drill or surgical robotics. DSG was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer. SpineGuard has engaged in multiple ESG initiatives.

    Seite 2 von 3



    Business Wire (engl.)
    0 Follower
    Autor folgen

    SpineGuard Announces its Q3 2023 Revenue - Seite 2 Regulatory News: SpineGuard (FR0011464452 – ALSGD), an innovative company that deploys its DSG (Dynamic Surgical Guidance) sensing technology to secure and streamline the placement of bone implants, announced today its third quarter 2023 revenue. …

    Schreibe Deinen Kommentar

    Disclaimer